LINKS
|

|
|
|
![]()
|

|
Structural
Genomics Consortium
The
Structural Genomics Consortium (SGC)
is a not-for-profit
organization that aims to determine the three dimensional structures of
proteins of medical relevance, and place them in the public domain
without
restriction. The SGC operates out of the Universities of Oxford
and Toronto
and Karolinska
Institutet, Stockholm. During the first phase of
the project, more
than 450 protein structures
were deposited in the PDB.
In its second funding phase (July
1 2007
- June 30 2011) SGC
aims
to determine more than
650 novel structures, including 9 structures
of human
integral membrane proteins. SGC works on a Target List of
~2,400
proteins with
relevance to human health comprising
proteins associated with diabetes, cancer, genetic and epigenetic
disease as
well as with infectious
diseases such as malaria.
SGC
Stockholm
The Stockholm
laboratory was established in 2005 after funding
had been
provided by the Swedish Foundation for Strategic Research (SSF), the
Knut and
Alice Wallenberg foundation (KAW), the
Swedish
Governmental Agency for Innovation Systems
(VINNOVA) and Karolinska Institutet. The laboratory is hosted by the Department
of Medical Biochemistry and Biophysics
at Karolinska
Institutet. Currently 25 researchers are employed by the project.
More
details regarding the SGC Stockholm research can be found under the Research
tab. Scientists
interested in collaborations are encouraged to contact us.
Structural
Genomics and Impact for Society
SGC
deposited its 400th structure into the Protein Data Bank in
March 2007, and is currently operating at a pace of 200 structures per
year. The vast amount of structural information generated by the SGC
is expected to have a tremendous impact on human health by furthering
our
understanding of relevant proteins - leading to new hypotheses and new
directions for biomedicinal research - and by supplying new targets for
therapeutic intervention. It will also provide the structural framework
for the
rational design of new or improved drugs that can inhibit or enhance
protein
function. The
significant contributions of structural biology to drug discovery are
well
documented (e.g. http://publications.nigms.nih.gov/structlife/chapter4.html).
|